Summit Therapeutics Inc. Increase (Decrease) in Accounts Receivable
Summit Therapeutics Inc. (SMMT) reported Increase (Decrease) in Accounts Receivable of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-24.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2025-02-24
- Summit Therapeutics Inc. increase (decrease) in accounts receivable for the quarter ending 2024-12-31 was $0.00.
- Summit Therapeutics Inc. increase (decrease) in accounts receivable for the quarter ending 2024-09-30 was $0.00.
- Summit Therapeutics Inc. increase (decrease) in accounts receivable for the quarter ending 2024-06-30 was $0.00.
- Summit Therapeutics Inc. increase (decrease) in accounts receivable for the quarter ending 2024-03-31 was $0.00.
- Summit Therapeutics Inc. increase (decrease) in accounts receivable for fiscal 2024 was $0.00.
- Summit Therapeutics Inc. increase (decrease) in accounts receivable for fiscal 2023 was -$359.00K.
- Summit Therapeutics Inc. increase (decrease) in accounts receivable for fiscal 2022 was -$975.00K, a 185.68% decline from fiscal 2021.
- Summit Therapeutics Inc. increase (decrease) in accounts receivable for fiscal 2021 was $1.14M.
| Period end | Increase (Decrease) in Accounts Receivable 3 month | Increase (Decrease) in Accounts Receivable 6 month | Increase (Decrease) in Accounts Receivable 9 month | Increase (Decrease) in Accounts Receivable 11 month | Increase (Decrease) in Accounts Receivable 12 month |
|---|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-24 | $0.00 derived: sum of 2 quarters · filed 2025-02-24 | $0.00 derived: sum of 3 quarters · filed 2025-02-24 | $0.00 10-K · filed 2025-02-24 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-30 | $0.00 derived: sum of 2 quarters · filed 2024-10-30 | $0.00 10-Q · filed 2024-10-30 | $0.00 derived: sum of 4 quarters · filed 2025-02-24 | |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $0.00 10-Q · filed 2024-08-06 | $0.00 derived: sum of 3 quarters · filed 2025-02-24 | -$3.00K derived: sum of 4 quarters · filed 2025-02-24 | |
| 2024-03-31 | $0.00 10-Q · filed 2024-05-01 | $0.00 derived: sum of 2 quarters · filed 2025-02-24 | -$3.00K derived: sum of 3 quarters · filed 2025-02-24 | -$9.00K derived: sum of 4 quarters · filed 2025-02-24 | |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-24 | -$3.00K derived: sum of 2 quarters · filed 2025-02-24 | -$9.00K derived: sum of 3 quarters · filed 2025-02-24 | -$359.00K 10-K · filed 2025-02-24 | |
| 2023-09-30 | -$3.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-30 | -$9.00K derived: sum of 2 quarters · filed 2024-10-30 | -$359.00K 10-Q · filed 2024-10-30 | $1.05M derived: sum of 4 quarters · filed 2025-02-24 | |
| 2023-06-30 | -$6.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | -$356.00K 10-Q · filed 2024-08-06 | $1.06M derived: sum of 3 quarters · filed 2025-02-24 | -$171.00K derived: sum of 4 quarters · filed 2025-02-24 | |
| 2023-03-31 | -$350.00K 10-Q · filed 2024-05-01 | $1.06M derived: sum of 2 quarters · filed 2025-02-24 | -$165.00K derived: sum of 3 quarters · filed 2025-02-24 | -$870.00K derived: sum of 4 quarters · filed 2025-02-24 | |
| 2022-12-31 | $1.41M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-24 | $185.00K derived: sum of 2 quarters · filed 2025-02-24 | -$520.00K derived: sum of 3 quarters · filed 2025-02-24 | -$975.00K 10-K · filed 2025-02-24 | |
| 2022-09-30 | -$1.23M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | -$1.93M derived: sum of 2 quarters · filed 2023-11-07 | -$2.39M 10-Q · filed 2023-11-07 | -$3.32M derived: sum of 4 quarters · filed 2023-11-07 | |
| 2022-06-30 | -$705.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | -$1.16M 10-Q · filed 2023-08-09 | -$2.09M derived: sum of 3 quarters · filed 2023-08-09 | -$726.00K derived: sum of 4 quarters · filed 2023-08-09 | |
| 2022-03-31 | -$455.00K 10-Q · filed 2023-05-11 | -$1.39M derived: sum of 2 quarters · filed 2023-05-11 | -$21.00K derived: sum of 3 quarters · filed 2023-05-11 | $569.00K derived: sum of 4 quarters · filed 2023-05-11 | |
| 2021-12-31 | -$932.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $434.00K derived: sum of 2 quarters · filed 2023-03-09 | $1.02M derived: sum of 3 quarters · filed 2023-03-09 | $1.14M 10-K · filed 2023-03-09 | |
| 2021-09-30 | $1.37M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $1.96M derived: sum of 2 quarters · filed 2022-11-09 | $2.07M 10-Q · filed 2022-11-09 | -$1.62M derived: sum of 4 quarters · filed 2022-12-21 | |
| 2021-06-30 | $590.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $704.00K 10-Q · filed 2022-08-11 | -$2.99M derived: sum of 3 quarters · filed 2022-12-21 | $533.00K derived: sum of 4 quarters · filed 2022-12-21 | |
| 2021-03-31 | $114.00K 10-Q · filed 2022-05-11 | -$3.58M derived: sum of 2 quarters · filed 2022-12-21 | -$57.00K derived: sum of 3 quarters · filed 2022-12-21 | -$1.34M derived: sum of 4 quarters · filed 2022-12-21 | |
| 2020-12-31 | -$3.69M derived: 10-K/A 12 month − 10-Q 9 month · filed 2022-12-21 | -$171.00K derived: sum of 2 quarters · filed 2022-12-21 | -$1.46M derived: sum of 3 quarters · filed 2022-12-21 | -$212.00K 10-K/A · filed 2022-12-21 | |
| 2020-09-30 | $3.52M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $2.23M derived: sum of 2 quarters · filed 2021-11-15 | $3.48M 10-Q · filed 2021-11-15 | ||
| 2020-06-30 | -$1.29M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | -$41.00K 10-Q · filed 2021-08-12 | |||
| 2020-03-31 | $1.25M 10-Q · filed 2021-05-17 | ||||
| 2019-12-31 | -$5.44M 10-K · filed 2021-03-31 | ||||
| 2019-09-30 | $5.97M derived: 10-Q 9 month − 8-K 6 month · filed 2020-11-16 | -$2.75M 10-Q · filed 2020-11-16 | |||
| 2019-06-30 | -$8.72M 8-K · filed 2020-09-29 | ||||
| 2019-01-31 | $2.47M 10-K · filed 2021-03-31 | ||||
| 2018-01-31 | $2.08M 8-K · filed 2020-09-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |